Literature DB >> 19331596

Solifenacin succinate for the treatment of overactive bladder.

Susan Hoffstetter1, Fah Che Leong.   

Abstract

UNLABELLED: Solifenacin succinate, a competitive muscarinic receptor antagonist, is one of the newer options for the treatment of overactive bladder in men and women.
OBJECTIVE: To review the pharmacology, efficacy and tolerability for the treatment of overactive bladder with solifenacin succinate.
METHODS: A literature search was done using the keywords YM905 and solifenacin succinate.
CONCLUSION: Solifenacin succinate was shown to be effective for symptom control with an increase in volume voided, improvement in quality of life and a decrease in a common side effect of dry mouth compared to other medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331596     DOI: 10.1517/17425250902762866

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  2 in total

1.  Incontinence medication response relates to the female urinary microbiota.

Authors:  Krystal J Thomas-White; Evann E Hilt; Cynthia Fok; Meghan M Pearce; Elizabeth R Mueller; Stephanie Kliethermes; Kristin Jacobs; Michael J Zilliox; Cynthia Brincat; Travis K Price; Gina Kuffel; Paul Schreckenberger; Xiaowu Gai; Linda Brubaker; Alan J Wolfe
Journal:  Int Urogynecol J       Date:  2015-09-30       Impact factor: 2.894

2.  Comparison of solifenacin and fesoterodine in treatment of overactive bladder.

Authors:  Önder Ercan; Bülent Köstü; Murat Bakacak; Yusuf Aytaç-Tohma; Bora Çoşkun; Fazıl Avcı; Erkan Efe
Journal:  Saudi Med J       Date:  2015-10       Impact factor: 1.484

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.